NCT00281866View on ClinicalTrials.gov

Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

October 31, 2006

Study Completion Date

March 31, 2007

Conditions
Head and Neck Cancer
Interventions
DRUG

erlotinib hydrochloride

Trial Locations (2)

28041

Hospital Universitario 12 de Octubre, Madrid

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00281866 - Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer | Biotech Hunter | Biotech Hunter